Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab
Ahmad A. Tarhini(UPMC Hillman Cancer Center), John M. Kirkwood(UPMC Hillman Cancer Center)
Cited by 309
Related Papers
Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects
|The Oncologist|2011|579
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced <i>BRAF</i>-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134
|Journal of Clinical Oncology|2022|427
Modulation of Signal Transducers and Activators of Transcription 1 and 3 Signaling in Melanoma by High-Dose IFNα2b
|Clinical Cancer Research|2007|110